<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574311</url>
  </required_header>
  <id_info>
    <org_study_id>PREFER-CPB01</org_study_id>
    <nct_id>NCT03574311</nct_id>
  </id_info>
  <brief_title>Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery</brief_title>
  <acronym>PREFER-CABG</acronym>
  <official_title>A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective or Urgent Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of single dose preoperative ferric&#xD;
      carboxymaltose in the prevention of postoperative infections and blood transfusions in&#xD;
      patients scheduled for cardiac surgery. Half of the patients will receive ferric&#xD;
      carboxymaltose and half of the patients physiological saline solution as placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled 1:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinding, study drug administration by separate staff blinded from participant and investigators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of allogeneic blood transfusion and/or nosocomial infection</measure>
    <time_frame>0-90 days</time_frame>
    <description>Composite of transfused red blood cell units and/or nosocomial infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>0-90 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU/CCU days</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days in the ICU (intensive care unit) and/or CCU (cardiac care unit)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative myocardial infarction</measure>
    <time_frame>3 days</time_frame>
    <description>MI (myocardial infarction) assessed by postoperative CK-Mbm or Troponin t levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on vasoactive drugs</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days on vasopressors (e.g. epinephrine, norepinephrine, milrinone etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>0-90 days</time_frame>
    <description>Days not on ventilator (intubated or non-invasive ventilation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKI (acute kidney injury)</measure>
    <time_frame>0-90 days</time_frame>
    <description>Rate of acute renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation (AF) or flutter</measure>
    <time_frame>0-90 days</time_frame>
    <description>New AF or flutter (i.e. patient without previous history of AF/flutter) assessed from ECG-telemetry during index hospitalization or ECG-verified AF/flutter after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute heart failure</measure>
    <time_frame>90 days</time_frame>
    <description>Acute congestive heart failure (diagnosed by a clinician) requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening heart failure</measure>
    <time_frame>0-90 days</time_frame>
    <description>Worsening to NYHA -class (New York Heart Association) III/IV or readmission for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed with self-reporting questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Postoperative Complications</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Aortic Aneurysm, Thoracic</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative 1000 mg intravenous single dose as 30 minute infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative 100 ml saline as 30 minute infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>A single dose of drug or placebo is administered preoperatively to participants</description>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiological saline</intervention_name>
    <description>Single infusion 100 ml physiological saline infusion preoperatively</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients presenting with cardiac disease requiring surgical operation&#xD;
&#xD;
          2. Open heart surgery is considered the best appropriate treatment strategy according to&#xD;
             the current guidelines.&#xD;
&#xD;
               -  significant three vessel disease&#xD;
&#xD;
               -  left main disease Â± single, two or three vessel disease&#xD;
&#xD;
               -  two-vessel disease with proximal LAD stenosis&#xD;
&#xD;
               -  coronary artery disease requiring revascularization not amenable to percutaneous&#xD;
                  coronary intervention&#xD;
&#xD;
               -  Aortic valve disease requiring aortic valve surgery&#xD;
&#xD;
               -  Mitral valve disease requiring surgical mitral surgery&#xD;
&#xD;
               -  Combined surgery for revascularization and valve disease&#xD;
&#xD;
               -  surgery of ascending aorta&#xD;
&#xD;
          3. Have provided signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 35 years&#xD;
&#xD;
          2. Patients requiring , emergency or salvage cardiac surgical operation&#xD;
&#xD;
          3. Participation in another clinical study or treatment with another investigational&#xD;
             product 30 days prior to randomization&#xD;
&#xD;
          4. Moribund patient not expected to survive surgery 12 months after surgery&#xD;
&#xD;
          5. Active malignant disease with a short life expectancy, not eligible for surgery&#xD;
&#xD;
          6. Hemoglobin levels &gt; 155 g/dL for women and &gt;167 g/dl for men (upper reference limits&#xD;
             for TYKSlab)&#xD;
&#xD;
          7. Ferritin levels &gt;150 ug/l for women and &gt;400 ug/l for men.&#xD;
&#xD;
          8. Renal dialysis therapy for chronic renal failure or severe preoperative renal&#xD;
             impairment (eGFR&lt;30ml/min).&#xD;
&#xD;
          9. Study treatment can't be infused during the required time window: minimum 48 hours and&#xD;
             maximum 21 days before the operation.&#xD;
&#xD;
         10. Ongoing oral or parenteral iron medication at the time of randomization&#xD;
&#xD;
         11. Iron or haemoglobin metabolism or synthesis disorders&#xD;
&#xD;
         12. Primary or secondary hemochromatosis (in males and postmenopausal females, a serum&#xD;
             ferritin value of over 300 ng/mL (670 pmol/L); and in premenopausal females, a serum&#xD;
             ferritin value of over 150[17] or 200[18] ng/mL (330 or 440 pmol/L) indicates iron&#xD;
             overload).&#xD;
&#xD;
         13. Porphyria cutanea tarda.&#xD;
&#xD;
         14. Liver failure (Child-Pugh class B or C).&#xD;
&#xD;
         15. Pregnancy.&#xD;
&#xD;
         16. Body weight less than 50kg.&#xD;
&#xD;
         17. Ongoing antibiotic treatment other than prophylactic urine tract infection&#xD;
             antibiotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jarmo M Gunn, adj. professor</last_name>
    <phone>+35823130000</phone>
    <email>jarmo.gunn@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuija Vasankari, RN</last_name>
    <phone>+35823130000</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarmo M Gunn, PhD</last_name>
      <phone>+35823130548</phone>
      <email>jarmo.gunn@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuija Vasankari, RN</last_name>
      <phone>+35823130000</phone>
      <email>tuija.vasankari@tyks.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CABG</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>intravenous iron</keyword>
  <keyword>postoperative infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

